Selected article for: "amino acid and peptide vaccine"
Author: Aparicio, Belén; Casares, Noelia; Egea, Josune; Ruiz, Marta; Llopiz, Diana; Maestro, Sheila; Olagüe, Cristina; González-Aseguinolaza, Gloria; Smerdou, Cristian; López-Díaz de Cerio, Ascensión; Inogés, Susana; Prósper, Felipe; Yuste, José R.; Carmona-Torre, Francisco; Reina, Gabriel; Lasarte, Juan J.; Sarobe, Pablo
Title: Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
  • Cord-id: wwyq89ua
  • Document date: 2021_9_27
    • ID: wwyq89ua
    Snippet: Identification of relevant epitopes is crucial for the development of subunit peptide vaccines inducing neutralizing and cellular immunity against SARS-CoV-2. Our aim was the characterization of epitopes in the receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein to generate a peptide vaccine. Epitope mapping using a panel of 10 amino acid overlapped 15-mer peptides covering region 401-515 from RBD did not identify linear epitopes when tested with sera from infected individuals or from
    Document: Identification of relevant epitopes is crucial for the development of subunit peptide vaccines inducing neutralizing and cellular immunity against SARS-CoV-2. Our aim was the characterization of epitopes in the receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein to generate a peptide vaccine. Epitope mapping using a panel of 10 amino acid overlapped 15-mer peptides covering region 401-515 from RBD did not identify linear epitopes when tested with sera from infected individuals or from RBD-immunized mice. However, immunization of mice with these 15-mer peptides identified four peptides located at region 446-480 that induced antibodies recognizing the peptides and RBD/S1 proteins. Immunization with peptide 446-480 from S protein formulated with Freund’s adjuvant or with CpG oligodeoxinucleotide/Alum induced polyepitopic antibody responses in BALB/c and C56BL/6J mice, recognizing RBD (titres of 3 × 10(4)–3 × 10(5), depending on the adjuvant) and displaying neutralizing capacity (80–95% inhibition capacity; p < 0.05) against SARS-CoV-2. Murine CD4 and CD8T-cell epitopes were identified in region 446-480 and vaccination experiments using HLA transgenic mice suggested the presence of multiple human T-cell epitopes. Antibodies induced by peptide 446-480 showed broad recognition of S proteins and S-derived peptides belonging to SARS-CoV-2 variants of concern. Importantly, vaccination with peptide 446-480 or with a cyclic version of peptide 446-488 containing a disulphide bridge between cysteines 480 and 488, protected humanized K18-hACE2 mice from a lethal dose of SARS-CoV-2 (62.5 and 75% of protection; p < 0.01 and p < 0.001, respectively). This region could be the basis for a peptide vaccine or other vaccine platforms against Covid-19.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and additional group: 1
    • absence presence and adenoviral vector: 1
    • absence presence and long sequence: 1, 2, 3
    • absence presence and long short: 1, 2, 3, 4, 5, 6, 7, 8
    • absence presence and long short term: 1, 2, 3, 4, 5
    • acute respiratory disease and additional group: 1, 2
    • acute respiratory disease and adenoviral vector: 1
    • acute respiratory disease and long sequence: 1
    • acute respiratory disease and long short: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory disease and long short term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute sars cov respiratory syndrome coronavirus and additional group: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and adenoviral vector: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and adjuvant alum adjuvant: 1, 2
    • acute sars cov respiratory syndrome coronavirus and adjuvant test: 1
    • acute sars cov respiratory syndrome coronavirus and long peptide: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and long sequence: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and long short: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and long short term: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25